Rating- neutral; Pharma sector- Poised for strong growth in Q1FY24
时间:2024-06-26 07:55:28 阅读(143)
We anticipate a positive performance from our pharmaceutical sector coverage in Q1FY24, driven by improved sales in the US market and strong performance across most branded markets. As the cost pressures gradually ease, we expect to see a robust y-o-y Ebitda growth of 22% (excluding BIOS and Mankind). In the hospital segment, we project a relatively stable performance compared to the previous quarter, with occupancy trends gradually returning to pre-Covid levels. For diagnostic companies, we anticipate a slight increase in non-Covid realisations per patient on a quarterly basis, supported by price hikes and higher volumes of non-Covid tests. Our top picks in the pharma sector are Sun Pharma (SUNP), Mankind, and Cipla. Although recent price increases may limit short-term upside, we maintain a positive outlook on APHS, Rainbow, and KIMS in the healthcare services sector.
Pharma: Improved US, healthy branded markets, yoy margin expansion in store
Hospitals: Steady quarter in store We expect a sequentially steady performance for the India-based hospitals, with lower occupancies being offset by higher ARPOB. For hospitals, we forecast a topline growth of 15% y-o-y in Q1FY24. Overall, we expect an Ebitda growth of 20% y-o-y for our hospitals.
Diagnostics: We expect an uptick in B2C sales growth
Regarding the diagnostic firms, we anticipate a slight increase in non-Covid revenue per patient q-o-q, supported by price adjustments and higher volumes of non-Covid tests. We have factored in a y-o-y growth of 8-12% in non-Covid sales for DLPL and METROHL. We expect a decrease in Covid-related sales for both compared to the last quarter. In Q1FY24, we project a 20% q-o-q Ebitda growth rate for DLPL and a 2% q-o-q growth rate for METROHL. The lower growth rate for METROHL is due to the loss of the NACO contract, which accounted for 4-5% of sales, starting from February 2023.
上一篇:Zomato share price plunges 14% intraday, hits new all-time low; check what’s fuelling the sell-off
下一篇:Zepto on track for $1 billion run rate in annual sales value
猜你喜欢
- Will Nifty reclaim 18400 or bears to grip D-St- Check US shares, Asian markets, FII activity, SGX Nifty, more
- Wipro share buyback- Board to mull 5th buyback in 7 years, to announce on 27 April along with Q4FY23 results
- Closing Bell- Indian Indices closed in red, Nifty settled below 19,400, Sensex below 64,850, Realty and Auto shines
- Woman jumps to death with six-month-old infant from 16th floor in Greater Noida
- Buy these two stocks for gains while Nifty remains in an up-trend, resistance at 17800
- US Stocks- Futures subdued ahead of December jobs report
- Chandigarh’s Growth Agenda- Amit Shah inaugurates nine projects, lays foundation for three more
- US Stocks- Wall Street set to slide on rising recession fears
- Buy these stocks for gains while Nifty’s short-term trend remains choppy, may retest 16800 support